Bacteriophages GMP

Phase 3

AAssistance Publique - Hôpitaux de Paris

Bacteriophages GMP is one of 9 therapeutic programs targeting Bacterial Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bacterial PneumoniaNot yet recruiting

Bacterial PneumoniaPhase 3

Not yet recruiting

Competition

Competitive Landscape

9 competitors in Bacterial Pneumonia

#DrugCompanyPhaseTrials

Ketek

Biaxin

Levaquin

2 4

Avycaz

PPhiladelphia Eye Associates

Approved

—5

Tygacil

PPrism Pharmaceuticals

Amikin

Teflaro

3 8

Bacteriophages GMP

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 9

Polymyxin B

MMahidol University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 3Not yet recruiting

Bacterial Pneumonia

NCT07804082

Clinical

Trials by Indication[1]

Bacterial Pneumonia1 trial

A Double-Blind, Placebo-Controlled Study of Nebulized Bacteriophages in Patients With Ventilator-Associated Pneumonia Due to Pseudomonas Aeruginosa

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07804082·184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bacteriophages GMP. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bacteriophages GMP. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Bacteriophages GMP

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Bacterial Pneumonia1 trial

References

Drug Info

Quick Facts

Related News